Chinook Therapeutics, Inc.

NasdaqGS:KDNY Stock Report

Market Cap: US$2.9b

Chinook Therapeutics Valuation

Is KDNY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KDNY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate KDNY's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate KDNY's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KDNY?

Other financial metrics that can be useful for relative valuation.

KDNY key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue450.5x
Enterprise Value/EBITDA-11.6x
PEG Ration/a

Price to Book Ratio vs Peers

How does KDNY's PB Ratio compare to its peers?

The above table shows the PB ratio for KDNY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.2x
JANX Janux Therapeutics
3.6x-22.7%US$2.3b
TPTX Turning Point Therapeutics
4.8x24.7%US$3.8b
APLS Apellis Pharmaceuticals
12.7x69.6%US$3.4b
CPRX Catalyst Pharmaceuticals
3.9x20.9%US$2.4b
KDNY Chinook Therapeutics
8.1x22.6%US$2.9b

Price-To-Book vs Peers: KDNY is expensive based on its Price-To-Book Ratio (8.1x) compared to the peer average (4.8x).

Price to Earnings Ratio vs Industry

How does KDNY's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.7%
 n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.7%
 n/an/an/a
No more companies

Price-To-Book vs Industry: KDNY is expensive based on its Price-To-Book Ratio (8.1x) compared to the US Biotechs industry average (1.5x).

Price to Book Ratio vs Fair Ratio

What is KDNY's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KDNY PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio8.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate KDNY's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst KDNY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$40.09
0%
9.4%US$47.00US$30.00n/a11
Sep ’25n/a
US$40.09
0%
9.4%US$47.00US$30.00n/a11
Aug ’25n/a
US$40.09
0%
9.4%US$47.00US$30.00n/a11
Jul ’25n/a
US$40.09
0%
9.4%US$47.00US$30.00n/a11
Jun ’25n/a
US$40.09
0%
9.4%US$47.00US$30.00n/a11
May ’25n/a
US$40.09
0%
9.4%US$47.00US$30.00n/a11
Apr ’25n/a
US$40.09
0%
9.4%US$47.00US$30.00n/a11
Mar ’25n/a
US$40.09
0%
9.4%US$47.00US$30.00n/a11
Feb ’25n/a
US$40.09
0%
9.4%US$47.00US$30.00n/a11
Jan ’25n/a
US$40.09
0%
9.4%US$47.00US$30.00n/a11
Dec ’24n/a
US$40.09
0%
9.4%US$47.00US$30.00n/a11
Nov ’24n/a
US$40.09
0%
9.4%US$47.00US$30.00n/a11
Oct ’24n/a
US$40.09
0%
9.4%US$47.00US$30.00n/a11
Sep ’24n/a
US$40.09
0%
9.4%US$47.00US$30.00n/a11
Aug ’24US$40.29
US$40.09
-0.5%
9.4%US$47.00US$30.00n/a11
Jul ’24US$38.42
US$39.18
+2.0%
12.1%US$47.00US$30.00n/a11
Jun ’24US$24.74
US$36.58
+47.9%
17.6%US$51.00US$30.00n/a12
May ’24US$19.84
US$37.17
+87.3%
18.1%US$51.00US$30.00n/a12
Apr ’24US$23.15
US$37.17
+60.5%
18.1%US$51.00US$30.00n/a12
Mar ’24US$22.95
US$36.82
+60.4%
18.8%US$51.00US$30.00n/a11
Feb ’24US$25.07
US$35.00
+39.6%
20.6%US$51.00US$28.00n/a9
Jan ’24US$26.20
US$35.00
+33.6%
20.6%US$51.00US$28.00n/a9
Dec ’23US$22.48
US$35.63
+58.5%
20.9%US$51.00US$28.00n/a8
Nov ’23US$21.96
US$35.13
+59.9%
19.2%US$48.00US$28.00n/a8
Oct ’23US$19.66
US$35.13
+78.7%
19.2%US$48.00US$28.00n/a8

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y